{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:04:44Z","timestamp":1780599884539,"version":"3.54.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12,15]]},"DOI":"10.1097\/qai.0b013e318271c2c7","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T18:20:00Z","timestamp":1355768400000},"page":"527-534","source":"Crossref","is-referenced-by-count":20,"title":["Reduced Levels of Serum FGF19 and Impaired Expression of Receptors for Endocrine FGFs in Adipose Tissue From HIV-Infected Patients"],"prefix":"10.1097","volume":"61","author":[{"given":"Jos\u00e9 M.","family":"Gallego-Escuredo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria del Mar","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Cabeza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angels","family":"Fontanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan Carles","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Villarroya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210131","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1089\/met.2009.0094","article-title":". Metabolic abnormalities and coronary heart disease risk in human immunodeficiency virus-infected adults.","volume":"8","author":"Pullinger","year":"2010","journal-title":"Metab Syndr Relat Disord"},{"key":"R2-1-20210131","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.beem.2010.12.001","article-title":"Adipose tissue biology and HIV-infection.","volume":"25","author":"Giralt","year":"2011","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R3-1-20210131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00441-010-1024-2","article-title":"Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease.","volume":"342","author":"Itoh","year":"2010","journal-title":"Cell Tissue Res"},{"key":"R4-1-20210131","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":". FGF-21 as a novel metabolic regulator.","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J Clin Invest"},{"key":"R5-1-20210131","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1210\/endo.143.5.8850","article-title":". Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity.","volume":"143","author":"Tomlinson","year":"2002","journal-title":"Endocrinology"},{"key":"R6-1-20210131","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1074\/jbc.M808818200","article-title":"Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis.","volume":"284","author":"Bhatnagar","year":"2009","journal-title":"J Biol Chem"},{"key":"R7-1-20210131","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1073\/pnas.0907812106","article-title":". Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in obob mice.","volume":"106","author":"Wu","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R8-1-20210131","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1198363","article-title":". FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis.","volume":"331","author":"Kir","year":"2011","journal-title":"Science"},{"key":"R9-1-20210131","doi-asserted-by":"crossref","first-page":"26687","DOI":"10.1074\/jbc.M704165200","article-title":". Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.","volume":"282","author":"Kurosu","year":"2007","journal-title":"J Biol Chem"},{"key":"R10-1-20210131","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.18632\/aging.100108","article-title":"Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis.","volume":"1","author":"Wu","year":"2009","journal-title":"Aging (Albany NY)"},{"key":"R11-1-20210131","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1097\/QAD.0b013e3283400088","article-title":". Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients.","volume":"24","author":"Domingo","year":"2010","journal-title":"AIDS"},{"key":"R12-1-20210131","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1055\/s-2007-985148","article-title":". Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus.","volume":"116","author":"Chen","year":"2008","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"R13-1-20210131","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":". Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans.","volume":"57","author":"Zhang","year":"2008","journal-title":"Diabetes"},{"key":"R14-1-20210131","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":". Obesity is a fibroblast growth factor 21 (FGF21)-resistant state.","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes"},{"key":"R15-1-20210131","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/ajcn\/64.5.685","article-title":". A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue.","volume":"64","author":"Lemieux","year":"1996","journal-title":"Am J Clin Nutr"},{"key":"R16-1-20210131","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.qai.0000167478.28051.3a","article-title":"Redefining lipodystrophy syndrome: risks and impact on clinical decision making.","volume":"39","author":"Lichtenstein","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R17-1-20210131","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/clinchem\/41.5.717","article-title":". Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin.","volume":"41","author":"Sugiuchi","year":"1995","journal-title":"Clin Chem"},{"key":"R18-1-20210131","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":". Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"R19-1-20210131","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/oby.2002.83","article-title":". Depot-specific expression of fibroblast growth factors in human adipose tissue.","volume":"10","author":"Gabrielsson","year":"2002","journal-title":"Obes Res"},{"key":"R20-1-20210131","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1021\/mp700105z","article-title":"Mini-review: endocrine actions of fibroblast growth factor 19.","volume":"5","author":"Jones","year":"2008","journal-title":"Mol Pharm"},{"key":"R21-1-20210131","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","article-title":". Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease.","volume":"139","author":"Dushay","year":"2010","journal-title":"Gastroenterology"},{"key":"R22-1-20210131","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/me.2010-0142","article-title":". Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse.","volume":"24","author":"Fon","year":"2010","journal-title":"Mol Endocrinol"},{"key":"R23-1-20210131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcp.20847","article-title":". Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling.","volume":"210","author":"Moyers","year":"2007","journal-title":"J Cell Physiol"},{"key":"R24-1-20210131","doi-asserted-by":"crossref","first-page":"627","DOI":"10.33549\/physiolres.932099","article-title":". Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR- agonist treatment.","volume":"60","author":"Mraz","year":"2011","journal-title":"Physiol Res"},{"key":"R25-1-20210131","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1365-2796.2006.01731.x","article-title":". Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man.","volume":"260","author":"Lundasen","year":"2006","journal-title":"J Intern Med"},{"key":"R26-1-20210131","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1592\/phco.30.1.17","article-title":". Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicity.","volume":"30","author":"McRae","year":"2010","journal-title":"Pharmacotherapy"},{"key":"R27-1-20210131","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/135965350300800614","article-title":". Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.","volume":"8","author":"Nolan","year":"2003","journal-title":"Antivir Ther"},{"key":"R28-1-20210131","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/QAD.0b013e32832b4377","article-title":". Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.","volume":"23","author":"Haubrich","year":"2009","journal-title":"AIDS"},{"key":"R29-1-20210131","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1177\/135965350601100610","article-title":". HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1HAART-associated lipodystrophy.","volume":"11","author":"Giralt","year":"2006","journal-title":"Antivir Ther"},{"key":"R30-1-20210131","doi-asserted-by":"crossref","first-page":"607902","DOI":"10.1155\/2009\/607902","article-title":"HIV-1 infection and the PPARgamma-dependent control of adipose tissue physiology.","volume":"2009","author":"Giralt","year":"2009","journal-title":"PPAR Res"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAI.0b013e318271c2c7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T21:21:33Z","timestamp":1687900893000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201212150-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,15]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e318271c2c7","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12,15]]}}}